Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

, AMGN

Amgen

$146.00

0.93 (0.64%)

16:12
11/29/16
11/29
16:12
11/29/16
16:12

Arrowhead to halt development of all EX1 programs, cut 30% of workforce

Arrowhead Pharmaceuticals (ARWR) announced a "strategic redeployment" of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneous and extra-hepatic delivery systems. Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. "Arrowhead remains committed to finding therapeutic options for patients with chronic hepatitis B infection and alpha-1 antitrypsin deficiency. The company intends to advance to the clinic two previously unannounced HBV and AATD programs using our subQ platform. Arrowhead has learned a great deal during prior HBV and AAT studies that will help drive the subQ programs efficiently. Existing preclinical subQ and extra-hepatic programs such as ARC-LPA and ARC-AMG1, which are partnered with Amgen (AMGN), ARC-F12, ARC-HIF2, and other unannounced programs are not affected by this decision," it said. The company is reducing its workforce by approximately 30%, while "maintaining full resourcing necessary to support current and potential future partner-based programs and Arrowhead's burgeoning pipeline." This structure should enable the company to continue to "develop its programs rapidly," and is intended to extend its cash runway into 2019. The company further noted: "The decision to discontinue development of EX1-containing programs was based primarily on two factors. First, during ongoing discussions with regulatory agencies and outside experts, it became apparent that there would be substantial delays in all clinical programs that utilize EX1, while the company further explored the cause of deaths in a non-clinical toxicology study in non-human primates. Second, Arrowhead has made substantial advances in RNA chemistry and targeting resulting in large potency gains for subQ administered and extra-hepatic RNAi-based development programs. In preclinical studies with the subQ platform, the company has obtained depth and duration of target gene knockdown approaching that of intravenously administered EX1-containing candidates, at lower doses and with good safety margins... In addition, across the ARC-520, ARC-521, and ARC-AAT clinical programs, laboratory values have not been deemed indicative of drug induced organ toxicity."

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

AMGN

Amgen

$146.00

0.93 (0.64%)

  • 29

    Nov

  • 29

    Nov

  • 19

    Jul

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
WBLR
08/19/16
INITIATION
Target $9
WBLR
Outperform
Arrowhead initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Arrowhead Pharmaceuticals with an Outperform rating and $9 price target.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
AMGN Amgen
$146.00

0.93 (0.64%)

11/07/16
MZHO
11/07/16
INITIATION
Target $164
MZHO
Buy
Amgen initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated Amgen with a Buy rating and a $164 price target.
11/08/16
ARGS
11/08/16
NO CHANGE
ARGS
Amgen weakness creates buying opportunity, says Argus
After Amgen's stock sunk 10% following its Q3 results, Argus says that the decline was triggered by "news that pricing power for Enbrel would be limited in 2017." However, the firm says that the company's growth outlook is "solid," while it has launched "promising new drugs." The firm keeps a Buy rating on the stock.
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."

TODAY'S FREE FLY STORIES

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

ABUS

Arbutus Biopharma

15:10
04/23/17
04/23
15:10
04/23/17
15:10
Hot Stocks
Arbutus reports ARB-1467 study data, plans additional trial in 2H »

Arbutus Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

ACHN

Achillion

$3.64

-0.02 (-0.55%)

, JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

15:05
04/23/17
04/23
15:05
04/23/17
15:05
Hot Stocks
Achillion reports updated data from Phase 2 JNJ-4178 study »

Achillion Pharmaceuticals…

ACHN

Achillion

$3.64

-0.02 (-0.55%)

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

BMY

Bristol-Myers

$53.48

0.04 (0.07%)

14:59
04/23/17
04/23
14:59
04/23/17
14:59
Hot Stocks
Bristol-Myers says '036 NASH study meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

14:52
04/23/17
04/23
14:52
04/23/17
14:52
General news
Breaking General news story  »

Fillon concedes as Le…

ALBO

Albireo Pharma

$20.66

-0.26 (-1.24%)

14:45
04/23/17
04/23
14:45
04/23/17
14:45
Hot Stocks
Albireo Pharma reports 'promising' A4250 data, sees Phase 3 trial start in 2H »

Albireo Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.62

-0.71 (-0.79%)

14:34
04/23/17
04/23
14:34
04/23/17
14:34
Hot Stocks
ShaveLogic says wins summary judgement over Gillette »

ShaveLogic issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ORIG

Ocean Rig UDW

$0.23

-0.0121 (-5.04%)

14:30
04/23/17
04/23
14:30
04/23/17
14:30
Hot Stocks
Ocean Rig UDW extends Drill Rigs early consent deadline »

Ocean Rig UDW announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SRG

Seritage Growth Properties

$42.86

-0.47 (-1.08%)

, SHLD

Sears

$13.39

-0.25 (-1.83%)

14:18
04/23/17
04/23
14:18
04/23/17
14:18
Periodicals
Seritage releasing efforts could deliver 'significant' growth, Barron's says »

Despite its significant…

SRG

Seritage Growth Properties

$42.86

-0.47 (-1.08%)

SHLD

Sears

$13.39

-0.25 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

ORLY

O'Reilly Automotive

$265.36

2.36 (0.90%)

, AAP

Advance Auto Parts

$146.84

0.28 (0.19%)

14:10
04/23/17
04/23
14:10
04/23/17
14:10
Periodicals
O'Reilly is top pick in auto parts retail, Barron's says »

O'Reilly Automotive…

ORLY

O'Reilly Automotive

$265.36

2.36 (0.90%)

AAP

Advance Auto Parts

$146.84

0.28 (0.19%)

AZO

AutoZone

$707.79

1.49 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 07

    Jun

HOG

Harley-Davidson

$55.81

-0.66 (-1.17%)

13:55
04/23/17
04/23
13:55
04/23/17
13:55
Periodicals
Harley-Davidson remains unattractive, Barron's says »

Investors should continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

ARNC

Arconic

$26.00

-0.11 (-0.42%)

, AA

Alcoa

$31.70

-0.34 (-1.06%)

13:51
04/23/17
04/23
13:51
04/23/17
13:51
Periodicals
Alcoa looks like safer bet over Arconic, Barron's says »

With "plenty of…

ARNC

Arconic

$26.00

-0.11 (-0.42%)

AA

Alcoa

$31.70

-0.34 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

INFY

Infosys

$14.48

0.01 (0.07%)

, WIT

Wipro

$9.70

-0.15 (-1.52%)

13:36
04/23/17
04/23
13:36
04/23/17
13:36
Periodicals
Indian outsourcers to feel pain from 'Hire American' push, Barron's says »

The Trump…

INFY

Infosys

$14.48

0.01 (0.07%)

WIT

Wipro

$9.70

-0.15 (-1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$28.41

-0.05 (-0.18%)

13:22
04/23/17
04/23
13:22
04/23/17
13:22
Periodicals
MGM Resorts earnings report unlikely to miss, Barron's says »

Investors shouldn't…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

13:04
04/23/17
04/23
13:04
04/23/17
13:04
Periodicals
Johnson & Johnson pullback could represent buy opportunity, Barron's says »

Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

SRPT

Sarepta

$32.61

0.07 (0.22%)

12:52
04/23/17
04/23
12:52
04/23/17
12:52
Periodicals
Sarepta may double or more, Barron's says »

Sarepta shares, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

, BAC

Bank of America

$22.71

-0.36 (-1.56%)

12:43
04/23/17
04/23
12:43
04/23/17
12:43
Periodicals
Major U.S. banks look attractive, Barron's says »

Bank stocks "look…

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 09

    May

  • 11

    May

  • 19

    May

  • 22

    May

  • 06

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 15

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.